An Early Phase 1 interventional study of BREAK and ONE in Pre-diabetes, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Colorado, Denver · Early Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 350 studies in Glucose Intolerance with a site in United States — 43 open to participants now, 65 under way, none of them phase 3. Glucose Intolerance · United States.
Among the 350 studies in Glucose Intolerance with a site in United States, this one is the 122nd largest by planned enrollment of the 307 interventional ones that give a count, is one of 25 that started in 2021, is one of 16 in phase 1, reaches primary completion later than 23 of the 64 other live ones, and was the 265th registered.
793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.
Browse Glucose Intolerance studies →43 of the 350 studies in Glucose Intolerance with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18–65
Applied Science & Performance Institute · Sites in United States
Ages 50–75 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–75
Pennington Biomedical Research Center · Sites in United States
Ages 25–50 · Healthy volunteers
Albert Einstein College of Medicine · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glucose Intolerance studies recruiting now, 13 (19%) set no upper age limit and 50 (74%) stop at 75 or younger; 9 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
350 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 36 · Phase 3 15 · Phase 4 28
First in 1994; this study’s year is marked. 25 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is above the median of 56 across 660 interventional studies indexed under Glucose Intolerance.
Median enrollment 50 across the 307 interventional studies, 107 across the 40 observational. Of the 261 that completed or were terminated, 100 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 350 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 4 studies filed under Glucose Intolerance — fewer than ten, so there is no comparison to draw.
25 of the studies in Glucose Intolerance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06921902Abbott Diabetes CareGlycemic Metrics and Patterns in People With and Without Prediabetes | 2026-12 |
| NCT05465616ViomeEfficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c | 2026-12-13 |
| NCT05041491University of Colorado, DenverBreaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes | 2026-12-15 |
| NCT06607341Johns Hopkins UniversityCommunity Engagement Alliance Against Disparities | 2026-12-20 |
Add all 25 to your calendar (.ics) → With an account.
Among the 350 studies in Glucose Intolerance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in people who achieve the recommended levels of PA. Preliminary experimental data suggest that breaking up prolonged sedentary time by performing multiple short bouts (5 min) of PA throughout the day, may improve glycemia more than performing a single continuous bout of PA, and thereby potentially be a novel strategy to prevent T2D. The improvement in glycemia was observed even when the total amount of PA and total energy expenditure were matched, suggesting that how and when PA is performed over the day may matter more than how much PA is done. However, important gaps in knowledge remain including: (1) whether similar benefits on glucose control would be observed in adults with prediabetes, a clinically relevant population that is at high risk of developing T2D; (2) whether these effects are sustained or diluted over time, and (3) what are the mechanistic underpinnings. To address these gaps, the investigators propose to measure the acute and chronic effects of PA breaks on glucose control and the underlying mechanisms in individuals at risk of developing T2D. Sedentary men and women with prediabetes (n=66, 50% F) will be randomized to either an intervention designed to interrupt SB with 5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/week (BREAK) or a control condition consisting of 45-min of brisk walking performed as a single daily continuous bout, 5 days/week (ONE). The two 3-months interventions will be matched for total active time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.
Behavioral: BREAK
Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.
Behavioral: ONE
The BREAK intervention is a physical activity regimen.
The ONE intervention is a physical activity regimen.
Glycemia
Plasma glucose concentration in mg/dL measured before and 30, 60, 90 and 120 min after an oral glucose tolerance test (OGTT, 75g glucose).
Time frame: Glucose concentration in mg/dl, measured at fasting, during a 2 hour OGTT and after
Insulinemia
Plasma insulin concentration in milli-international units per milliliter (mUI/mL) measured before and 30, 60, 90 and 120 min after an oral glucose tolerance test (OGTT, 75g glucose).
Time frame: Plasma insulin concentration in mUI/mL, measured at fasting, during a 2 hour OGTT and after
Mean interstitial glucose concentration
Mean interstitial glucose concentration measured continuously by a glucose monitor placed on the tricep for 24hours for 10 days.
Time frame: Before and after 1 month and 3 months of intervention
Daily glycemia variability
Standard deviation (SD) of interstitial glucose concentration measured continuously by a glucose monitor placed on the tricep 24hours throughout 10 days.
Time frame: Before and after 1 month and 3 months of intervention
Fasting A1c concentration
Fasting A1c concentration expressed in %
Time frame: Time Frame: Before and after 1 month and 3 months of intervention
Fasting fructosamine concentration
Fasting fructosamine concentration in umol/L
Time frame: Before and after 1 month and 3 months of intervention
12-hour exogenous glucose oxidation
Rates of carbon-13 (13C) recovery (% of the dose) in expired carbon dioxide (CO2) following the ingestion of U-13C-glucose in both breakfast and lunch meals.
Time frame: Before and after 1 month of intervention
12-hour endogenous glucose oxidation
Rates of D2 recovery (% of the dose) in expired urines following the infusion of (2,2H2) glucose.
Time frame: Before and after 1 month of intervention
12 hour CO2 production
CO2 production measured by indirect calorimetry (ParvoMedics TrueOne® 2400, Salt Lake City) for 20 minutes every hour from 0800h to 1800h.
Time frame: Before and after 1 month of intervention
12 hour O2 production
O2 production measured by indirect calorimetry (ParvoMedics TrueOne 2400, Salt Lake City) for 20 minutes every hour from 0800h to 1800h.
Time frame: Before and after 1 month of intervention
12 Urine excretion
Urine will be measured every hour from 0730h to 1830h
Time frame: Before and after 1 month of intervention
Glucose kinetics
Steele's equation for non-steady-state will be used to compute rate of appearance of total glucose (RaT) and rate of appearance of exogenous glucose (RaE), as well as the rates of disappearance (RdT and RdE) from the percentage of \[6,6-2H2\]glucose6 and of 13C-glucose in plasma glucose61. Endogenous glucose production (EGP) will be computed as RaT-RaE. Nonoxidative glucose disposal (NOGD) will be calculated by subtracting total carbohydrate oxidation from (RdT + RdE). Plasma glucose utilization will be assumed to be equivalent to RdT as has been confirmed previously. Muscle glycogen utilization during the active period will be calculated as total carbohydrate utilization during exercise minus plasma glucose utilization during exercise.
Time frame: Before and after 1 month of intervention
Fasting and postprandial glucose
Fasting and postprandial glucose in mg/dl measured in response to standard lunch
Time frame: Before and after 1 month of intervention
Fasting and postprandial insulin
Fasting and postprandial insulin in ml/iu measured in response to standard lunch
Time frame: Before and after 1 month of intervention
Fasting and postprandial C-Peptide
Fasting and postprandial C-peptide nmol/mL measured in response to standard lunch
Time frame: Before and after 1 month of intervention
Fasting and postprandial glucagon
Fasting and postprandial glucagon in pg/mL measured in response to standard lunch
Time frame: Before and after 1 month of intervention
Fasting and postprandial catecholamines
Fasting and postprandial catecholamines in pg/mL measured in response to standard lunch
Time frame: Before and after 1 month of intervention
Skeletal muscle content of protein kinase B (Akt) (Aktser473/total)
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure protein kinase B (Akt) (Aktser473/total) using western blotting.
Time frame: Before and after 1 month of intervention
Skeletal muscle content of ACC (ACCS79/ total)
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure ACC (ACCS79/ total) using western blotting.
Time frame: Before and after 1 month of intervention
Skeletal muscle content of TBC1D4 (AS160/ total)
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure TBC1D4 (AS160/ total) using western blotting.
Time frame: Before and after 1 month of intervention
Skeletal muscle content of COX4
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure citrate synthase (COX4) using western blotting.
Time frame: Before and after 1 month of intervention
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →